Dr. Freedland on role of cabazitaxel in prostate cancer paradigm

Stephen J. Freedland, MD, discusses current practice patterns with cabazitaxel in prostate cancer and the potential to use the therapy earlier in treatment sequencing.

Stephen J. Freedland, MD, discusses practice patterns with cabazitaxel in prostate cancer that have emerged following the results of the pivotal CARD trial, which showed an improvement in clinical outcomes with cabazitaxel (Jevtana) versus an androgen receptor pathway inhibitors (ARPI) (abiraterone acetate [Zytiga] or enzalutamide [Xtandi]) in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel who had progressed within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide).

Freedland is director of the Center for Integrated Research in Cancer and Lifestyle, co-director of the Cancer Genetics and Prevention Program and associate director for faculty development at the Cancer Institute. He is a faculty physician in the Division of Urology at the Cedars-Sinai Surgery Department.

Freedland is a speaker and consultant for Jevtana developer Sanofi, as well as several other pharmaceutical companies.